Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Neurocognitive Measurements in Depressed Patients
NCT04916548Phase 2Completed
- Sponsor
- Rebecca Price
- Start
- Sep 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by Rebecca Price. Primary endpoints: fMRI Intrinsic Connectivity: Default Mode Network at 24 hours, fMRI Intrinsic Connectivity: Frontoparietal Control Network at 24 hours and 2 more. Started Sep 2021; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04916548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916548.